Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells - Trial NCT06026995
Access comprehensive clinical trial information for NCT06026995 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chongqing University Cancer Hospital and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 174 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chongqing University Cancer Hospital
Timeline & Enrollment
Phase 4
Mar 01, 2022
Jun 01, 2024
Primary Outcome
The proportion of patients with CD34+ cells โฅ2ร106/kg
Summary
This study is a randomized controlled, open and multi-center clinical study. Patients who
 meet the selection criteria and do not meet the exclusion criteria are randomly given
 PEG-rhG-CSF with a fixed dose of 12mg when white blood cells reach the lowest point, or given
 rhG-CSF with a daily mobilization of 5-10ฮผ g/kg until the collection is completed, so as to
 evaluate the effectiveness and safety of PEG-rhG-CSF in mobilizing autologous stem cells for
 lymphoma and multiple myeloma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06026995
Non-Device Trial